Speaker
Description
Introduction
The performance of hemodialysis membranes depends on uremic toxin clearance, biocompatibility, mechanical properties, and the ultrafiltration characteristics of the hemodialyzer [1]. The clearance rate can be controlled by membrane properties, such as thickness, morphology, and pore size, as well as the surface properties of the membrane [2].
Methods
Novel hemodialysis membranes were fabricated using the phase inversion technique, based on cellulose acetate (CA) and polylactic acid (PLA), and further modified with hydrophilic polymers (PVP, PEG) as well as metallic nanoparticles, including copper, platinum, and selenium. These nano-enhanced materials were comprehensively characterised in terms of their physicochemical and mechanical properties, as well as their biocompatibility. In addition, toxin removal efficiency and membrane flux were also evaluated.
Results and Discussion
This work highlights the potential of incorporating metallic nanoparticles into CA/PLA membranes to tailor critical properties for hemodialysis applications. The presence of nanomaterials improves the hydrophilicity and elasticity of membranes while maintaining biocompatibility and high clearance efficiency. Additionally, nano-enhanced membranes exhibit antibacterial activity, which may reduce the risk of potential bloodstream infections—a major cause of death and hospitalisation among hemodialysis (HD) patients [3].
The findings offer a promising pathway toward next-generation dialysis membranes with enhanced durability, mechanical stability, biocompatibility, and resistance to protein fouling.
References:
[1] Yan M, Bai Q. et al. Overview of hemodialysis membranes: Methods and strategies to improve hemocompatibility, Journal of Industrial and Engineering Chemistry 2024, 139, 94-110.
[2] Bonomini M., Piscitani L., Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy, Biomedicines 2022,10(4), 844
[3] Pravda M.R., Maor Y., Blood stream Infections in chronic hemodialysis patients - characteristics and outcomes, BMC Nephrol 2024, 25, 3.
42705232977